CAMBRIDGE, England & BAD HOMBURG, Germany--(BUSINESS WIRE)--Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that ...
A study led by the School of Engineering of the Hong Kong University of Science and Technology (HKUST) has developed an innovative method that overcomes the limitations of traditional additive ...
Site will serve as company’s new headquarters and expands capacity and capabilities for induced pluripotent stem cell development and ...
Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an ...
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment for non-responsive or relapsing hematological malignancies, providing an intensive, personalized form of immunotherapy. It ...
Additive manufacturing of cellular lattice structures has emerged as a transformative approach to fabricating lightweight, high-performance materials with precise control over internal architecture.
SEAL BEACH, Calif. & SAN DIEGO--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, and Shoreline ...
According to Kite, the median turnaround time for Yescarta is expected to be reduced from 16 days to 14 days. The Food and Drug Administration (FDA) has approved a manufacturing process change for ...
For some cases of cancer, the starting point of a new treatment is already inside the patient. Cell therapy provides another option for advanced blood cancers that have not responded to other drugs.
Zachary Sun, PhD, co-founder and CSO of Tierra Biosciences, spoke last year at SynBioBeta about cell-free protein synthesis. He and Mike Nemzek, CEO of Tierra, speak to GEN about the potential for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results